Cadrenal Therapeutics (NASDAQ: CVKD) Adds HIT, Factor XIa Drugs in Quiet Expansion

Cadrenal Therapeutics (NASDAQ: CVKD) adds HIT, Factor XIa drugs in quiet expansion

Cadrenal Therapeutics broadens its anticoagulation platform with tecarfarin, a Factor XIa program and Phase 2 VLX-1005 for HIT, setting up new trial catalysts.

Cadrenal acquires VLX-1005 for patients with HIT - BioTuesdays

Cadrenal Therapeutics (NASDAQ: CVKD) has announced the acquisition of VLX-1005—a first-in-class, Phase 2 12-LOX inhibitor—along with additional 12-lipoxygenase (12-LOX) assets from closely held Veralox Therapeutics, for the treatment of heparin-induced thrombocytopenia (HIT). According to Cadrenal, the acquisition immediately strengthens its pipeline with a late-stage, first-in-class drug candidate targeting a critical immune signaling pathway. …

Release - Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT) - Channelchek

Open the article to view the coverage from channelchek.com